- $430.67m
- $372.45m
Brief: Camac Partners says Forte Biosciences Board should promptly announce a plan to return capital to shareholders
Brief: Forte Biosciences Announces Q2 2022 Results
Brief: Forte Biosciences - Filed New Prospectus Supplement Relating To Offer Of Shares Covering Sales Of Up To Additional $2.7 Million Shares
Brief: ATG Fund II Llc Reports Stake In Forte Biosciences, Says Shares Were Undervalued
Brief: Funicular Funds Says Willing To Engage In Discussions With Forte Biosciences
Brief: Forte Biosciences Says Board Authorized, Declared Dividend Of One Right For Each Outstanding Share Of Common Stock
Brief: BML Investment Partners - On July 6, Sent Letter To Forte Biosciences CEO, Saying BML Believes Co Should Liquidate And/Or Return Cash To Shareholders
Brief: Funicular Funds Reports 7.5% Stake In Forte Biosciences Inc
Brief: Forte Biosciences Appoints Hubert Chen As Chief Scientific Officer And President
Forte Biosciences jumps after top shareholder tells co to liquidate
Brief: Bml Investment Partners - Reports 8.94% Stake In Forte Biosciences Inc As Of May 24, 2022 - SEC Filing
Brief: Forte Biosciences, Inc. Announces First Quarter 2022 Results And Provides Business Update
Forte Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Forte Biosciences Inc - Entered Into An At Market Issuance Sales Agreement With Ladenburg Thalmann & Co
Forte Biosciences Inc expected to post a loss of 32cents a share - Earnings Preview
Brief: Forte Biosciences - On Feb 1, Co Provided Notice Of Termination Of Patent License Agreement With National Institute Of Allergy & Infectious Diseases
U.S. STOCKS ON THE MOVE-Adobe, Under Armour, Lennar, gold stocks
Forte Biosciences Inc reports results for the quarter ended in September - Earnings Summary
U.S. STOCKS ON THE MOVE-Twist Bioscience, Box, Support.com